Assignment 1: Fragile X Syndrome Case Study – Genetic Counseling and Clinical Correlation

Course context and weighting

Course level: Graduate/upper‑division Advanced Pathophysiology / Advanced Health Assessment (Nursing or NP track).
Assessment type: Individual written assignment / case study analysis.
Assessment number: Assignment 1 (Week 3–5, depending on course schedule).
Length: Approximately 4–5 double‑spaced pages (excluding title page and reference list) or about 1,200–1,800 words.
Weighting: Typically 15–25% of total course grade (adjust locally).

Case scenario

Lisa Anderson, a 22‑year‑old Caucasian single parent, is referred to the genetic counseling service by her son’s pediatric Nurse Practitioner. She has a 3‑year‑old boy with global developmental delay and small joint hyperextensibility. Molecular testing has confirmed a diagnosis of Fragile X‑associated intellectual disability (full FMR1 mutation). Lisa is currently 14 weeks pregnant with her second child. The extended family history is otherwise unremarkable for intellectual disability, autism, or known genetic syndromes.

Assignment overview

In this assignment you will integrate molecular genetics, pathophysiology, and advanced health assessment to analyse the Fragile X syndrome case of Lisa Anderson and her family. You are expected to move beyond description and demonstrate critical reasoning regarding inheritance patterns, clinical manifestations, genetic risk, and implications for nurse practitioner‑led counseling and early intervention.

[4][5][1]

Purpose statement

The purpose of this 4–5 page paper is to apply advanced understanding of X‑linked inheritance, trinucleotide repeat disorders, and Fragile X syndrome (FXS) pathogenesis to a realistic clinical scenario, and to articulate evidence‑informed counseling points for a pregnant patient with a known FMR1 mutation in the family.

Task instructions

Write a clearly structured, APA‑formatted paper that addresses the headings below. Use current, peer‑reviewed sources and authoritative guidelines (e.g., StatPearls, national genetics organisations, CDC, NIH) to support your discussion.

[5][1][4]

I. Introduction

• Introduce Fragile X syndrome as an inherited cause of intellectual disability and neurodevelopmental impairment.
• State the overall purpose of the paper and briefly signpost the main sections (pathogenesis, clinical manifestations, inheritance, recurrence risk, and implications for the unborn child).

II. Genetic mutation responsible for Fragile X‑associated intellectual disability

• Identify the FMR1 gene, its chromosomal location, and the CGG trinucleotide repeat expansion that characterises Fragile X syndrome.

[1][5]

• Define normal, intermediate (“grey zone”), premutation, and full mutation ranges in terms of CGG repeat numbers and methylation status.

[3][1]

• Differentiate between premutation carriers and individuals with full mutation, noting associated Fragile X–associated conditions (FXPOI, FXTAS) where relevant.

[5][1]

III. Pathogenesis and clinical syndrome

Describe and discuss how the FMR1 mutation leads to the specific clinical features seen in Lisa’s son.

• Explain how loss or marked reduction of fragile X mental retardation protein (FMRP) disrupts synaptic development, neuronal plasticity, and brain connectivity, resulting in developmental delay and intellectual disability.

[6][1]

• Link altered connective tissue integrity to joint hyperextensibility, scoliosis, and other musculoskeletal findings.

[7][1]

• Describe typical physical and behavioural phenotypes in males with Fragile X syndrome, including long narrow face, large ears, macrocephaly, macro‑orchidism (large testes emerging in later childhood), autistic features, anxiety, and hyperactivity.

[8][6][1]

• Briefly address common comorbidities such as otitis media, seizures, cardiac issues (e.g., mitral valve prolapse), and autism spectrum disorder.

[7][8][1]

• Relate these mechanisms directly to Lisa’s 3‑year‑old son’s developmental delay and joint laxity.

IV. Probable carrier and phenotypic expression in parents and grandparents

• Identify which parent is the most probable carrier of the FMR1 mutation in this scenario and justify your answer using X‑linked inheritance principles.

[3][1]

• Explain why Lisa and her mother (and possibly other female relatives) may be premutation or full‑mutation carriers who are phenotypically unaffected or only mildly affected, referring to X‑inactivation and variable FMRP expression.

[1][5]

• Discuss why the absence of an obvious family history does not exclude FXS and how size mosaicism, AGG interruptions, and small family size can mask the pattern.

[3][5][1]

V. Recurrence risk and implications for the unborn child

• Explain recurrence risk for Lisa’s current pregnancy, differentiating between male and female fetuses, based on her presumed carrier status and X‑linked inheritance.

[4][1][3]

• Clarify that risk estimates depend on whether Lisa carries a premutation or full mutation, the number of CGG repeats, and the presence of AGG interruptions that may stabilise the repeat.

[5][1][3]

• Discuss the likelihood that:
  1. a male fetus will be affected with Fragile X syndrome (and likely severity),
  2. a female fetus will be affected or be a carrier, including expected variability in clinical expression.
• Briefly describe available prenatal diagnostic options (e.g., chorionic villus sampling, amniocentesis with FMR1 molecular testing) and when they are indicated, acknowledging ethical, psychosocial, and timing considerations.

[1][5]

VI. Role of the nurse practitioner and genetic counseling considerations

• Summarise the nurse practitioner’s role in coordinating genetic testing, interpreting reports at a basic level, and referring to specialist genetic services when appropriate.

[4][5]

• Outline key counseling points for Lisa regarding:
  1. inheritance and recurrence risk for current and future pregnancies,
  2. gender‑related differences in clinical severity,
  3. options for prenatal and preconception testing (including reproductive planning),
  4. early intervention services and developmental supports for her son and potentially affected offspring.
• Include brief mention of psychosocial support, communication with family members, and implications for extended relatives who may also be carriers.

[4][5]

VII. Conclusion

• Provide a concise synthesis that:
  1. reiterates the link between FMR1 mutation, FMRP deficiency, and Lisa’s son’s clinical presentation,
  2. summarises who is likely to be a carrier in the family and why they may be phenotypically unaffected,
  3. restates the approximate likelihood that the unborn child will be affected or a carrier, and
  4. highlights the nurse practitioner’s responsibilities in counseling, referral, and early intervention.

Requirements and formatting

• Length: Approximately 4–5 double‑spaced pages (excluding title page and references).
• Format: APA 7th edition (running head if required by your institution, page numbers, level headings, in‑text citations, reference list).
• Font and spacing: 12‑point Times New Roman, double‑spaced, 2.54 cm / 1‑inch margins.
• Sources: Minimum of 5 current scholarly sources (2018–2026). Prioritise peer‑reviewed journal articles, clinical guidelines, and authoritative texts. You may also cite reputable organisations (e.g. CDC, NIH, national genetics or Fragile X foundations).

[5][1][4]

• Original work: Paraphrase in your own words, integrate citations throughout, and adhere to your institution’s academic integrity policy.

Marking rubric (Assignment 1 – Fragile X Syndrome Case Study)

1. Content: Application and analysis (60%)

2. Quality of supporting research and sources (20%)

3. Organisation, academic writing, and APA presentation (20%)

Short sample answer content (SEO‑oriented, not for submission)

Fragile X syndrome arises when a CGG trinucleotide repeat in the FMR1 gene on the X chromosome expands into the full mutation range and becomes hypermethylated, which silences gene transcription and markedly reduces FMRP production. Reduced FMRP disrupts synaptic plasticity and dendritic spine maturation, which helps to explain the combination of global developmental delay, autistic features, and attention difficulties that often appear in early childhood. In Lisa Anderson’s case, her son’s cognitive delay and joint hyperextensibility are consistent with the recognised Fragile X phenotype in males who carry a fully mutated FMR1 allele without a second normal X chromosome to compensate. Because Lisa is the biological mother of an affected boy and there is no family history suggesting paternal transmission, she is the most likely carrier, probably with either a premutation or full mutation that shows reduced penetrance due to X‑inactivation skewing. For her current pregnancy, each male fetus has a substantial risk of being affected with Fragile X syndrome, whereas each female fetus has a high probability of being a carrier, with widely variable clinical expression depending on repeat size and FMRP levels.

[6][8][3][4][5][1]

When nurse practitioners counsel patients in similar situations, they need to integrate Mendelian risk estimates with contemporary data on repeat instability, AGG interruptions, and the psychosocial burden families experience as they weigh options such as chorionic villus sampling or amniocentesis. There is growing emphasis on early developmental surveillance and intervention for infants at known genetic risk, because timely speech‑language therapy, behavioural supports, and family education may improve functional outcomes even though the underlying mutation remains unchanged. In practice, that means clinicians must be able to explain complex molecular reports in plain language, to map those findings onto concrete decisions about pregnancy and child development, and to coordinate interprofessional referrals to genetics, psychology, early childhood services, and community Fragile X organisations.

[9][6][3][4][5][1]

Suggested references (2018–2026, APA 7th)

These are exemplars you can build into the “required reading / learning resources” block or recommend to students.

• Hagerman, R. J., Protic, D., Rajaratnam, A., Salcedo‑Arellano, M. J., Aydin, E. Y., & Schneider, A. (2018). Fragile X‑associated neuropsychiatric disorders (FXAND). Frontiers in Psychiatry, 9, 564. https://doi.org/10.3389/fpsyt.2018.00564
• Hunter, J. E., Berry‑Kravis, E., Martin, E. G., Herring, A. H., & Rohena, L. (2019). Fragile X syndrome: Pediatric primary care management. Pediatrics, 144(6), e20191608. https://doi.org/10.1542/peds.2019-1608
• Nolin, S. L., Glicksman, A., Tortora, N., Allen, E., Macpherson, J., & Hadd, A. G. (2019). Expansions and contractions of the FMR1 CGG repeat in 5,508 transmissions of normal, intermediate, and premutation alleles. American Journal of Medical Genetics Part A, 179(5), 1148–1156. https://doi.org/10.1002/ajmg.a.61167
• RACGP. (2023). Fragile X syndrome and associated conditions. In Genomics in general practice. The Royal Australian College of General Practitioners. https://www.racgp.org.au/clinical-resources/clinical-guidelines/genomics-in-general-practice/fragile-x-syndrome

[4]

• Stone, W. L., Basit, H., & Lozano, R. (2023). Fragile X syndrome. In StatPearls. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK459243/